(Las Vegas, Nevada, United States)  As per DelveInsight’s assessment, globally, Crohn’s Disease pipeline constitutes 90+ key companies continuously working towards developing 90+ Crohn’s Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. 

 

“Crohn’s Disease Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Crohn’s Disease Market.

 

The Crohn’s Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Crohn’s Disease Pipeline Report:

• Companies across the globe are diligently working toward developing novel Crohn’s Disease treatment therapies with a considerable amount of success over the years. 
• Crohn’s Disease companies working in the treatment market are Morphic Therapeutic, Orchard Therapeutics, Thetis Pharmaceuticals, AstraZeneca, Immunic, Suzhou Connect Biopharmaceuticals, Pfizer, Bristol-Myers Squibb, Eisai Inc, Janssen Pharmaceutical, Eli Lilly and Company, Gilead Sciences, RedHill Biopharma, Celgene Corporation, AstraZeneca, and others, are developing therapies for the Crohn’s Disease treatment 

• Emerging Crohn’s Disease therapies in the different phases of clinical trials are- MORF 057, OTL-104, TP-317, AZD 7798, IMU 856, CBP-307, PF-06651600, Deucravacitinib, E6011, Guselkumab, Mirikizumab, Filgotinib, RHB-104, Ozanimod, Brazikumab, and others are expected to have a significant impact on the Crohn’s Disease market in the coming years. 
• In May 2023, For those with moderate to severe active Crohn’s disease who did not respond well to or were intolerant of one or more tumour necrosis factor blockers, the FDA has approved Rinvoq (upadacitinib). The first oral medicine for the management of Crohn’s disease that has received FDA approval is called Rinvoq.
• In February 2023, Eli Lilly and Janssen worked together to address the paucity of paediatric treatments for Crohn’s disease. Eli Lilly and Janssen’s partnership was made in order for the two businesses to pool their resources and expedite the review of their respective businesses’ assets, mirikizumab and Tremfya (guselkumab).
• In February 2023, Positive results from the Phase I study of AGMB-129 for the treatment of Fibrostenosing Crohn’s Disease (FSCD) were released by Agomab Therapeutics. The oral, GI-restricted, small molecule kinase ALK5 (TGFbRI or ALK5) inhibitor AGMB-129 was tested in this study to determine its safety, tolerability, and pharmacokinetics (PK) in healthy volunteers. A well-known master fibrosis regulator is TGFb.
• In February 2023, The topline findings from DIVERSITY, a global Phase 3 trial to assess the safety and effectiveness of filgotinib, 100mg or 200mg once daily, during induction and maintenance treatment of biologic-nave and biologicexperienced patients with moderate to severe Crohn’s disease (CD), were released by Galapagos NV.

 

Crohn’s Disease Overview

A long-lasting inflammatory condition of the gastrointestinal tract, Crohn’s disease causes the intestinal wall’s serosa and mucosa to become inflamed. It is a chronic condition that recurs frequently. Crohn’s disease may at first just affect a small portion of the digestive tract, but it has the potential to spread widely.

 

Get a Free Sample PDF Report to know more about Crohn’s Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/crohns-disease-cd-pipeline-insight

 

Emerging Crohn’s Disease Drugs Under Different Phases of Clinical Development Include:

• MORF 057: Morphic Therapeutic
• OTL-104: Orchard Therapeutics
• TP-317: Thetis Pharmaceuticals
• AZD 7798: AstraZeneca
• IMU 856: Immunic
• CBP-307: Suzhou Connect Biopharmaceuticals
• PF-06651600: Pfizer
• Deucravacitinib: Bristol-Myers Squibb
• E6011: Eisai Inc
• Guselkumab: Janssen Pharmaceutical
• Mirikizumab: Eli Lilly and Company
• Filgotinib: Gilead Sciences
• RHB-104: RedHill Biopharma
• Ozanimod: Celgene Corporation
• Brazikumab: AstraZeneca

 

Crohn’s Disease Route of Administration

Crohn’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

 

Crohn’s Disease Molecule Type

Crohn’s Disease Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

 

Crohn’s Disease Pipeline Therapeutics Assessment

• Crohn’s Disease Assessment by Product Type
• Crohn’s Disease By Stage and Product Type
• Crohn’s Disease Assessment by Route of Administration
• Crohn’s Disease By Stage and Route of Administration
• Crohn’s Disease Assessment by Molecule Type
• Crohn’s Disease by Stage and Molecule Type

DelveInsight’s Crohn’s Disease Report covers around 90+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Further Crohn’s Disease product details are provided in the report. Download the Crohn’s Disease pipeline report to learn more about the emerging Crohn’s Disease therapies

 

Some of the key companies in the Crohn’s Disease Therapeutics Market include:

Key companies developing therapies for Crohn’s Disease are – Janssen, RedHill Biopharma, Amgen, Pfizer, Prometheus Biosciences, AgomAb Therapeutics, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, HAV Vaccines Ltd, Enzo Biochem Inc., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Pfizer, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, Soligenix, Immunic, Pfizer, Atlantic Healthcare, 4D Pharma, and others.

 

Crohn’s Disease Pipeline Analysis:

The Crohn’s Disease pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Crohn’s Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Crohn’s Disease Treatment.
• Crohn’s Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Crohn’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Crohn’s Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Crohn’s Disease drugs and therapies

 

Crohn’s Disease Pipeline Market Drivers

• High prevalence of Crohn’s Disease, increase in Drug Development for Crohn’s treatment, change in lifestyle patterns are some of the important factors that are fueling the Crohn’s DiseaseMarket.

 

Crohn’s Disease Pipeline Market Barriers

• However, lack of early diagnosis of the disease, high cost associated with the treatment and other factors are creating obstacles in the Crohn’s Disease Market growth.

 

Scope of Crohn’s Disease Pipeline Drug Insight    

• Coverage: Global
• Key Crohn’s Disease Companies: Morphic Therapeutic, Orchard Therapeutics, Thetis Pharmaceuticals, AstraZeneca, Immunic, Suzhou Connect Biopharmaceuticals, Pfizer, Bristol-Myers Squibb, Eisai Inc, Janssen Pharmaceutical, Eli Lilly and Company, Gilead Sciences, RedHill Biopharma, Celgene Corporation, AstraZeneca, and others
• Key Crohn’s Disease Therapies: MORF 057, OTL-104, TP-317, AZD 7798, IMU 856, CBP-307, PF-06651600, Deucravacitinib, E6011, Guselkumab, Mirikizumab, Filgotinib, RHB-104, Ozanimod, Brazikumab, and others
• Crohn’s Disease Therapeutic Assessment: Crohn’s Disease current marketed and Crohn’s Disease emerging therapies
• Crohn’s Disease Market Dynamics: Crohn’s Disease market drivers and Crohn’s Disease market barriers 

 

Request for Sample PDF Report for Crohn’s Disease Pipeline Assessment and clinical trials

 

Table of Contents 

1. Crohn’s Disease Report Introduction

2. Crohn’s Disease Executive Summary

3. Crohn’s Disease Overview

4. Crohn’s Disease- Analytical Perspective In-depth Commercial Assessment

5. Crohn’s Disease Pipeline Therapeutics

6. Crohn’s Disease Late Stage Products (Phase II/III)

7. Crohn’s Disease Mid Stage Products (Phase II)

8. Crohn’s Disease Early Stage Products (Phase I)

9. Crohn’s Disease Preclinical Stage Products

10. Crohn’s Disease Therapeutics Assessment

11. Crohn’s Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Crohn’s Disease Key Companies

14. Crohn’s Disease Key Products

15. Crohn’s Disease Unmet Needs

16 . Crohn’s Disease Market Drivers and Barriers

17. Crohn’s Disease Future Perspectives and Conclusion

18. Crohn’s Disease Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/acral-lentiginous-melanoma-market